FIGURES
Figure 1. Longitudinal time course of anti-S-protein IgG titers in saliva from uninfected participants who received three homologous doses of the mRNA-1273 (Moderna) vaccine (n = 28). Anti-S-protein IgG titers waned 9-150-fold in the months following the second dose of mRNA-1273. However, a robust recall 2 to 238-fold of anti-S-protein IgG titers in saliva occurred immediately following a third dose. The dotted line box denotes the timing participants received their third dose.
Figure 2. Longitudinal time course of anti-S-protein IgG titers in saliva from uninfected participants who received three homologous doses of the BNT162b2 (Pfizer-BioNTech) vaccine (n = 29). Anti-S-protein IgG titers waned 7-105-fold in the months following the second dose of BNT162b2. However, a robust recall 20 to 255-fold of anti-S-protein IgG titers in saliva occurred immediately following a third dose. The dotted line box denotes the timing participants received their third dose.
Figure 3. Anti-S-protein IgG titer peaks for second and third dose in mRNA-1273 cohort. The second versus third dose peaks were 750 ± 362 ng/mL and 801 ± 556 ng/mL (n = 28) which was not a statistically significant difference (p = 0.666).
Figure 4. Anti-S-protein IgG titer peaks for second and third dose in BNT162b2 cohort. The second versus third dose peaks were 591 ± 842 ng/mL and 1377 ± 1633 ng/mL (n = 29) which was a statistically significant difference (p = 0.0021).